MinorEnrollment closed, study ongoingShow 4 more changesShow less
Primary completion moved earlier from Sep 29, 2027 to Aug 30, 2027
Eligibility criteria expanded, about 9 words
Secondary endpoints: details revised at 2 of 28 entries
Site details revised at 57 of 57 sites
MinorTrial sites expanded: 54 → 57 locations
Eligibility criteria shortened, about 15 words
Secondary endpoints: 8 to 28
v21
MinorStudy sites: 53 to 54v20
MinorTrial sites expanded: 49 → 53 locationsv19
MinorTrial sites expanded: 46 → 49 locationsv18
MinorTrial sites expanded: 42 → 46 locationsv17
MinorTrial sites expanded: 38 → 42 locationsv16
MinorTrial sites expanded: 34 → 38 locationsv15
MinorStudy sites: 32 to 34v14
MinorTrial sites expanded: 28 → 32 locationsv13
MinorStudy sites: 26 to 28v12
MinorStudy sites: 24 to 26v11
MinorStudy sites: 23 to 24v10
MinorStudy sites: 19 to 23v9
MinorStudy sites: 15 to 19v8
MinorRe-verified, no change to tracked fieldsv7
MinorStudy sites: 13 to 15v6
MinorStudy sites: 12 to 13v5
MinorStudy sites: 8 to 12v4
MinorStudy sites: 5 to 8
Start date changed from estimate of Dec 17, 2025 to Nov 25, 2025
v3
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 5
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.